NFKB1 and breast cancer: The results showed that the secretion of TNF-α, IL-6 and IL-1β were all decreased after AT-I treatment, and we concluded that AT-I could suppress tumorigenesis in breast cancer via inhibiting TLR4/NF-κB pathway, and down-regulate downstream pro-inflammatory cytokines.